MedTrace Logo

Study of the Vascular Effects of Serelaxin

NCT01979614 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-07-01

Study results available
· View outcomes & findings →

Summary

This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.

Conditions

Interventions

DRUG

Serelaxin

Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution

OTHER

Placebo

5% v/v glucose solution

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-03
Primary Completion
2016-08-17
Completion
2016-08-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979614 on ClinicalTrials.gov